 |
A
call for sponsorship to support the running and future development
of Glycosmedia |
| |
Click on the above headline for an overview
of the Glycosmedia diabetes news service and our call for sponsorship.
Brief details on how sponsorship will work can be seen here. For further details please contact (Jim Young, Editor-in-Chief) |
| |
|
|
From
Race Cars and Google Doodles to Day Spas and Night Lights: |
| |
U.S. Prepare to Join World Diabetes Day Celebrations
on November 14 (International Diabetes Federation) |
| |
|
|
World
Diabetes Day |
| |
11-days to go (World Diabetes Day) |
| |
|
|
Can
type 2 diabetes be prevented in UK general practice? A lifestyle-change
feasibility study |
| |
A lifestyle-change intervention feasibility
programme for pre-diabetic patients was implemented in general
clinical practice. The potential of a low-glycaemic-load diet to
be more effective than a low-fat diet in promoting change in the
features associated with progression to diabetes is worthy of further
investigation (PubMed) |
| |
|
|
GPs'
approach to insulin prescribing in older patients: a qualitative
study |
| |
In order to improve prescribing for increasing
numbers of older people with type 2 diabetes, more education for
GPs, specialist support, and use of allied health professionals
is needed (PubMed) |
| |
|
|
Tight
control of blood glucose and cardiovascular disease |
| |
A strong effect that develops slowly but persists
for years (BMJ) |
| |
|
|
Oral
GLP-1 Study Presented at the EASD Conference in Rome |
| |
Results from a preclinical study on Axcess™ oral
formulated GLP-1 analogues have been presented in a poster presentation
during the European Association for the Study of Diabetes (EASD)
meeting in Rome (Diabetology) |
| |
|
|
Repeat
Dosing Data for Capsulin Phase II in type 2 diabetes presented
at the EASD Conference in Rome |
| |
Diabetology Limited, announced results from
the 10-day repeat-dosing of Capsulin™ oral insulin in patients with type 2 diabetes at the European Association for
the Study of Diabetes (EASD) meeting in Rome (Diabetology) |
| |
|
|
GSK
Believes There Is No Liver Safety Issue With AVANDIA |
| |
GlaxoSmithKline issued the following response
to a petition filed by Public Citizen to the U.S. Food and Drug
Administration (FDA) on Avandia (R) (rosiglitazone maleate), a
highly effective therapy for treating type 2 diabetes when used
in the appropriate patient population (Market Watch) |
| |
|
|
Influential
consumer group files petition to get Avandia banned |
| |
The influential consumer group Public Citizen
has called on US regulators to ban GlaxoSmithKline’s Avandia, claiming that the diabetes drug causes death from liver failure “and has many other life-threatening risks that far outweigh its benefits”. (PharmaTimes) |
| |
|
|
GI
News |
| |
November 2008 (GI News, University of Sydney,
Australia) |
| |
|
|
Health
Minister to launch new subsidy |
| |
The Minister for Health and Ageing, the Hon
Nicola Roxon MP, will this Saturday launch the ‘Type 1 Diabetes Insulin Pump Program’ – a new collaboration between the Juvenile Diabetes Research Foundation (JDRF),
Diabetes Australia and the Department of Health and Ageing (Diabetes
Australia) |
| |
|
|
Sources
of funding |
| |
If you know of any sources of funding that we
can contact to support the running and future development of Glycosmedia
then please mail Jim Young, Editor-in-Chief jim@glycosmedia.com |
| |
|
